|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions.
|
30481266 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, glycolysis-related enzymes, such as LDHA and PKM2, were upregulated in BRAF V600E </span>mutant thyroid cancer specimens, thereby promoting glycolysis.
|
30768848 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutations are common in papillary thyroid carcinoma (PTC) and some de-differentiated thyroid cancers.
|
31529211 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In thyroid cancer, TPO expression is decreased partly by the BRAF(V600E) mutation, with direct impact on significant hormone production.
|
30742860 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, glycolysis-related enzymes, such as LDHA and PKM2, were upregulated in BRAF V600E </span>mutant thyroid cancer specimens, thereby promoting glycolysis.
|
30768848 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutations are common in papillary thyroid carcinoma (PTC) and some de-differentiated thyroid cancers.
|
31529211 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In thyroid cancer, TPO expression is decreased partly by the BRAF(V600E) mutation, with direct impact on significant hormone production.
|
30742860 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions.
|
30481266 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We demonstrate detection of hallmark BRAF V600E mutations by NGS within infarcted tissue of thyroid carcinomas after FNA.
|
29868707 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer.
|
29295876 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data support the role of IL6/STAT3 signaling pathway in modulating TC cell response to PLX4032 and candidate IL6 targeting as a strategy to improve the activity of PLX4032 in BRAF V600E TC cells.
|
29969659 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In summary, the present study demonstrated that thyroid cancer harboring the BRAF V600E mutation was resistant to a selective BRAF inhibitor due to reactivation of the MAPK pathway.
|
29616135 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
|
30036146 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma.
|
29579361 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF V600E mutation was detected in the PTCs of the two patients with thyroid cancer.
|
29593792 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations were likely to occur in BRAF V600E positive TC.
|
30024548 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF V600E mutation was detected in the PTCs of the two patients with thyroid cancer.
|
29593792 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We demonstrate detection of hallmark BRAF V600E mutations by NGS within infarcted tissue of thyroid carcinomas after FNA.
|
29868707 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer.
|
29295876 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations were likely to occur in BRAF V600E positive TC.
|
30024548 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma.
|
29579361 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In summary, the present study demonstrated that thyroid cancer harboring the BRAF V600E mutation was resistant to a selective BRAF inhibitor due to reactivation of the MAPK pathway.
|
29616135 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data support the role of IL6/STAT3 signaling pathway in modulating TC cell response to PLX4032 and candidate IL6 targeting as a strategy to improve the activity of PLX4032 in BRAF V600E TC cells.
|
29969659 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
|
30036146 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This represents a novel mechanism in BRAF V600E-promoted PTC aggressiveness and identifies WIPF1 as a novel therapeutic target for thyroid cancer.
|
27863429 |
2017 |